Dengue Literature Review

Guzman2016 - Dengue Infection

11 min read

Guzman2016 - Dengue Infection

Full citation: Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Halstead SB. Dengue infection. Nature Reviews Disease Primers, 2, 16055 (2016). https://doi.org/10.1038/nrdp.2016.55

Raw file: [[raw/Guzman2016.pdf]]

Summary

This Nature Reviews Disease Primers article is the most comprehensive single-paper overview in the wiki, covering the full scope of dengue virus biology and disease: epidemiology and global burden, virology and molecular biology, pathophysiology, host-virus interactions, diagnosis, vaccine development, vector control, clinical management, and research priorities. The authorship is a who’s-who of dengue research: Guzman and Izquierdo (IPK, Havana — the same group behind the Garcia2009/2010 Cuban cohort studies), Gubler (arguably the field’s founding epidemiologist), and Halstead (the original ADE hypothesis proponent).

The paper argues that dengue control is technically feasible but requires sustained international commitment. Dengue is framed as a disease of the future — with increasing urbanisation, climate change, and movement of both vectors and viruses, the current >30-fold increase in incidence over recent decades is likely to continue without coordinated multi-sector intervention. The paper synthesises the state of play across vaccines (CYD-TDV approved but with a critical seronegative safety signal), vector control (Wolbachia and sterile males showing promise), and diagnostics (NS1 antigen enabling earlier detection than IgM serology).

The pathophysiology sections are particularly relevant to this wiki’s autoimmunity thread: they establish that sNS1 acts as a direct TLR4 ligand (activating macrophages and PBMCs independently of antibody cross-reactivity), binds thrombin in vivo to prolong APTT, and disrupts endothelial barrier integrity — all via the protein itself, not anti-NS1 autoantibodies. This provides a mechanistically distinct complement to the Lin group’s molecular mimicry model.

Study Design

  • Type: Disease Primer / Comprehensive narrative review
  • Sample size: N/A (review); covers primary data from multiple landmark trials and epidemiological studies
  • Setting: Global; draws on evidence from Asia, Americas, Africa, Europe; particular strength in Cuba (Guzman/Izquierdo), Americas (Gubler), and SE Asia (Halstead)
  • Population: All dengue-affected populations across the epidemiological literature

Key Findings

Global Epidemiology

  • 3.6 billion people at risk; 390 million DENV infections/year; 96 million symptomatic; 2 million severe; ~21,000 deaths/year

  • 30-fold increase in incidence in recent decades; endemic in Eastern Mediterranean, American, South-East Asian, Western Pacific, and African WHO regions; sporadic in Europe and USA

  • Global economic cost estimated at US2.2 billion/year in the Americas alone (2000–2007)
  • Higher incidence in Asia (modal age 5–15 years); Americas modal age 19–40 years

Virology

  • Four serotypes (DENV-1–4) each grouped into genotypes; 30% polyprotein divergence between serotypes; genotypic differences influence epidemic potential and transmission efficiency
  • Enveloped particles ~500 Å; positive-sense ssRNA ~11 kb encoding 3 structural proteins (C, prM/M, E) and 7 non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5)
  • E Protein: 90 tightly packed monomers on viral surface; DI-DII-DIII domain organisation; DIII binds host cell receptors; DII fusion loop (pH-dependent endosomal fusion); prM/M forms distinguish immature from mature particles
  • NS1 Protein: 46 kDa glycoprotein; three forms (ER-resident, membrane-anchored, secreted sNS1); sNS1 detectable from day 1 of fever; blood levels correlate with peak viraemia and disease severity in secondary infection; activates macrophages/PBMCs via TLR4; disrupts endothelial barrier integrity; binds thrombin in vivo; prolongs APTT in human platelet-deficient plasma; inhibits prothrombin activation

Pathophysiology

  • Vascular permeability: Not caused by endothelial cell death or direct infection; resolves rapidly during convalescence (implying reversible soluble mediator rather than structural damage); NS1 is the leading candidate for triggering barrier dysfunction via TLR4; APTT values are the strongest correlate of vascular permeability in dengue patients; onset at defervescence, not peak viraemia
  • Thrombocytopaenia: Two mechanisms — transient bone marrow suppression of all blood cell lineages (early febrile phase; probably IFN-β mediated, by analogy with LCMV model) + peripheral platelet destruction; platelet counts can fall to 5,000/ml (normal ~200,000/ml)
  • Coagulopathy: Prolonged APTT; reduced fibrinogen; mild increase in procoagulant markers; not classic DIC; NS1 binds thrombin in vivo and prolongs APTT; heparan/chondroitin sulfate shed from glycocalyx contributes to anticoagulant state
  • Complement activation: Classical pathway via circulating immune complexes in secondary infection; alternative pathway in primary infections of infants; NS1 activates complement by the alternative pathway
  • Liver: Hepatomegaly in 55% DHF vs 18% DF (P<0.01); AST/ALT elevated in 60–90% children with DHF; Councilman bodies (apoptotic hepatocytes engulfed by Kupffer cells) — classic histopathological finding; jaundice rare despite liver enlargement

Host Immune Response and ADE

  • Homotypic immunity: lifelong after primary infection; only a small fraction of circulating antibodies are neutralising
  • Heterotypic cross-protection: initial cross-protection after first infection (~2 months); protection against severe disease (~2 years)
  • ADE: DENVs are “conditionally virulent” — pre-infection partial immunity (sensitisation) is the key condition for severe disease; third and fourth infections typically mild or asymptomatic; severe disease most common in secondary infection
  • Maternal antibody ADE: infants born to immune mothers have protective maternal antibodies initially; when antibodies decline below the neutralising threshold (~40-day half-life), a brief window of ADE-mediated severe disease risk opens during primary infant infection
  • Longer interval between infections increases DHF risk: DENV2 secondary infection separated by 20 years → 8× higher DHF rate than if separated by 4 years
  • T cell role: CD8+ T cell immunity largely mediated by NS protein epitopes; both antibodies and T cells required for protection

Host Genetics (Table 2)

Gene VariantPopulationAssociation
FCGR2A (H/H131)CubaSusceptibility to DF or DHF
FCGR2A (R/R131)CubaResistance to DHF; better clinical outcome
HLA-A*0207ThailandSusceptibility to DHF
HLA-DRB1*0901VietnamProtection from DHF
DCSIGN1 CD209-336GIndiaSusceptibility to DHF
IL-10 ACC/ATA haplotype + TNF-308ACubaSusceptibility to DSS
VDR 352CVietnamResistance to DSS

Diagnosis

  • Viraemia: detectable 24–48 hours before fever onset; lasts 5–6 days; infective virus, specific RNA, and NS1 all detectable in blood/serum/plasma
  • Detection tiers: RT-PCR/real-time RT-PCR (most sensitive/specific; reference centres); virus isolation (gold standard but resource-intensive); NS1 antigen (early window; ELISA or rapid test); IgM ELISA (most widely used; from day 5–6 of symptoms); IgG seroconversion (confirmation)
  • Post-2015 diagnostic challenge: Zika virus (flavivirus) causes IgM cross-reactivity with dengue; new dual-detection algorithms required

Vaccines

  • CYD-TDV (Dengvaxia; Sanofi Pasteur): Phase III in >30,000 children across 10 countries; overall efficacy 56.5% (Asia) and 60.8% (Americas); >80% against DHF; protects seropositive (previously infected) individuals; seronegative children ≤5 years at vaccination had 5× the hospitalisation rate of controls; approved in Mexico, Philippines, Brazil for ages 9–45 years (at least 70% of whom should have prior dengue antibodies)
  • DENVax (TAK-003; Takeda): Chimeric DENV2 PDK-53 backbone; phase II at time of publication; well-tolerated; neutralising antibody seroconversion to all 4 serotypes
  • TV003 (US NIAID/Instituto Butantan): Single dose; 100% protection against virologically confirmed dengue in human challenge study (21 vaccinated volunteers vs. 20/20 controls infected)
  • Key vaccine challenges: balanced tetravalent immunity; risk of ADE from partial/waning immunity; no validated animal model; correlates of protection not fully established

Vector Control

  • Wolbachia: Natural bacterial parasite of insects; wMel strain adapted to Ae. aegypti; reduces mosquito lifespan; increases DENV resistance; spreads through natural mating (cytoplasmic incompatibility); sustainable; advanced field trials in Asia, South America, Central America
  • Sterile male (SIT): Males carry dominant lethal gene; progeny die as larvae; rapid population reduction but not sustainable
  • Integrated approach required: no single tool sufficient; Partnership for Dengue Control coordinates multi-tool strategies
  • Cuba and Singapore: temporary successes (Cuba 1981–2010; Singapore 1968+) ultimately failed due to re-introduction from endemic neighbours and economic constraints

Quality of Life and Long-Term Effects

  • Most cases resolve within 1 week; adults take longer than children
  • At 6 months post-acute illness: weakness (27.6%), headache (14.8%), arthralgias (10.6%)
  • At 2 years: persistence of some dengue symptoms confirmed (corroborating Garcia2009 - Long-term Clinical Symptoms Post-Dengue)
  • Neurological complications: encephalopathy, encephalitis, GBS, transitory Parkinsonism, dengue-related maculopathy
  • Haematological: haemophagocytic lymphohistiocytosis (HLH) as a rare dengue-associated condition

Methods Used

  • RT-PCR (DENV RNA detection and serotype identification; real-time quantification of viraemia)
  • NS1 Antigen Detection (early diagnostic window; sNS1 ELISA and rapid test)
  • IgM-IgG Serology ELISA (routine dengue serology; IgM from day 5–6; IgG seroconversion)
  • PRNT (gold standard neutralising antibody titres; reference laboratory level)
  • Virus isolation (mosquito cell lines; gold standard but resource-intensive; reference level)

Entities Mentioned

  • NS1 Protein (central to pathogenesis: TLR4 activation, thrombin binding, endothelial disruption, viraemia biomarker)
  • E Protein (structural protein; receptor binding; fusion; vaccine target; DIII neutralising epitopes)
  • DENV-1 (serotype; epidemiological role; Santiago de Cuba 1997 epidemic context)
  • DENV-2 (serotype; Asian vs American genotype virulence; classic secondary infection serotype)
  • DENV-3 (serotype; displacement dynamics; Cuba 2001 epidemic)
  • DENV-4 (serotype; Cuba 2006 epidemic — the Garcia2009/2010 cohort context)
  • Aedes aegypti (principal vector; full vector biology; Singapore/Cuba control programmes)
  • Aedes albopictus (secondary vector; enabling sporadic transmission in Europe/USA)
  • CYD-TDV (Dengvaxia; approved vaccine; seronegative enhanced disease signal)
  • Wolbachia (biological vector control; wMel strain; field trials)
  • FcγRIIa Receptor (Table 2: FCGR2A H131 → susceptibility; R131 → resistance; Cuba data)

Concepts Addressed

Relevance & Notes

This is the single most comprehensive source in the wiki and the primary reference for general dengue biology. It is the only paper authored by the Garcia2009/2010 group (Guzman, Izquierdo) that also covers global context, making it an important bridge between the Cuba-specific findings and the broader dengue literature.

Key additions to existing wiki threads:

The NS1-TLR4 and NS1-thrombin mechanisms (direct protein effects) are mechanistically distinct from the Lin group’s anti-NS1 autoantibody model. The two mechanisms are not mutually exclusive: sNS1 may simultaneously (a) activate TLR4 directly → cytokines/endothelial damage, and (b) stimulate anti-NS1 antibody production → molecular mimicry → platelet/endothelial cross-reactivity. This two-pathway model (direct and antibody-mediated NS1 effects) is the most complete current picture of NS1’s pathogenic role.

The CYD-TDV safety signal (5× hospitalisation in seronegative ≤5-year-olds) is direct clinical validation of the ADE hypothesis: a vaccine that creates partial cross-reactive immunity in naïve individuals appears to replicate the ADE-mediated risk of a first natural infection in sensitised hosts. This is the most important real-world ADE datapoint in the wiki.

The APTT-vascular permeability correlation (“APTT values are the strongest correlate of vascular permeability”) is notable: it connects the coagulation interference pathway (NS1-thrombin, WGNGCG E protein homology from Lin2011) directly to the primary clinical endpoint of DHF (plasma leakage). If APTT reflects both coagulopathy and vascular leakage risk, then the coagulation-targeting mechanisms described in Lin2011 and this paper may be more central to DHF pathogenesis than previously appreciated.

The 6-month symptom persistence data (weakness 27.6%, headache 14.8%, arthralgias 10.6%) independently confirms and extends the Garcia2009 2-year follow-up finding, from a different author group and a different timepoint, adding confidence to the existence of post-dengue syndrome beyond a single Cuban cohort.

The FcγRIIa data from Table 2 is drawn from the same Cuban cohort as Garcia2009/Garcia2010 — it is not an independent replication but a cross-citation. This is a limitation when assessing the generalisability of the FcγRIIa findings.

Questions Raised

  1. The NS1-TLR4 direct activation mechanism (Guzman2016) and the anti-NS1 molecular mimicry mechanism (Lin2006/Lin2011) have both been demonstrated independently — have they been shown to operate simultaneously in the same patient, and can their relative contributions to vascular leakage be disentangled?
  2. The APTT-vascular permeability correlation suggests coagulation interference is proximal to plasma leakage — does treating coagulopathy (e.g. with anti-NS1 antibodies) prevent vascular leakage in animal models?
  3. The CYD-TDV seronegative enhanced disease signal: does the antibody profile in vaccinated seronegative breakthrough-disease patients resemble the profile in natural secondary infection DHF (i.e., do they have the same IGHG1/plasmablast enrichment described in Sungnak2025)?
  4. Does the longer-interval DHF risk (20-year gap → 8× higher than 4-year gap) reflect declining heterotypic cross-neutralisation, or is there also accumulated molecular mimicry/autoantibody evolution over a longer inter-infection interval?
  5. TV003’s 100% human challenge protection with a single dose — is the protection mediated by CD8 T cells (the protective correlate from Sungnak2025) or by neutralising antibodies, and which mechanism does it preferentially induce?

Graph View

Backlinks